A Study of LY3437943 in Healthy Participants With a High Body Mass Index

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT05959096
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • LY3437943 — DRUG
    Administered SC
  • LY3437943 — DRUG
    Administered IV

Study Details

The study is conducted in two parts (Part A and B). The main purpose of this study is to look at the amount of the LY3437943 that gets into the blood stream and how long it takes the body to get rid of it when given subcutaneously (SC, under the skin) in the upper arm and thigh compared to the abdomen in healthy participants with high body mass index (BMI) in Part A. In Part B, the participants receive LY3437943 intravenously (IV, through a vein) where the safety and tolerability of LY3437943 are evaluated and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 157 days and 99 days for Part A and Part B, respectively.

Key Dates

Start date
Jul 18, 2023
Status verified
Sep 2024
Primary completion
Jul 25, 2024
Completion
Jul 25, 2024

Study Design

Enrollment
85 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3437943 (Part A)
    LY3437943 administered subcutaneously (SC) in either thigh, upper arm, or abdomen
  • Experimental: LY3437943 (Part B)
    LY3437943 administered intravenously (IV)

Primary Outcome Measure

Part A: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943 [ Time Frame: Predose on Day 1 up to 43 days postdose (Part A) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDaytona BeachFlorida32117-

Find similar trials in Daytona Beach, FL

Related Studies